TGAT
V3VGn
Market cap59mUSD
Oct 18, Last price
15.60EUR
Name
Vita 34 AG
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
FamiCord AG engages in the collection, logistics, processing, and storage of stem cells from umbilical cord blood, umbilical cord tissue, and other postnatal tissues, serving as a full-service provider for cryopreservation. It also engages in the development of products and drugs derived from cells, tissues, and blood for medical applications. Additionally, FamiCord is active in Cell & Gene therapies and operates as a CDMO. The company was founded by Eberhard F. Lampeter on April 28, 1997 and is headquartered in Leipzig, Germany.
Related entities
Subsidiaries (3)
KRIO Intezet Sejt- es Szovetbank Zartkoruen Mukodo Reszvenytarsasag
SECUVITA SL
Branches
SECUVITA SL
Key people
Alexander Granderath
Independent Chairman of the Supervisory Board · since 2021
Chairman of the Management Board, Chief Executive Officer · since 2025
Chairman of the Supervisory Board · since 2024
Member of the Management Board, Chief Commercial Officer · since 2022
Thomas Pfaadt
Chief Financial Officer, Member of the Management Board · since 2024
Peter Greiner
Deputy Chairman of the Supervisory Board · since 2024
Frank Koehler
Independent Member of the Supervisory Board · since 2020
Independent Member of the Supervisory Board · since 2021
Paul Owsianowski
Member of the Supervisory Board · since 2022
Ursula Schuetze-Kreilkamp
Independent Member of the Supervisory Board · since 2021
Legal address
Perlickstraße 5
Leipzig, SN 04103
DE
Leipzig, SN 04103
DE
Headquarters
Perlickstr. 5
Leipzig, SN 04103
DE
Leipzig, SN 04103
DE
Previous name
Vita 34 AG
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||